RxDoctor Payments Data

Conner Moslander, DO

Pulmonary Disease · Tulsa, OKNPI 1114422052

Payments from drug & device makers

What this record shows

This record is dominated by education: $5,500 of the $8,931 with a category attached, or 61.6%. Intuitive Surgical accounts for 80.2% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $8,326, more than ten times the $76 reported in 2022.

$8,931in general payments, 2019–2025

Across 94 payments — averaging $95.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$7K
  • AstraZeneca$444
  • GSK$192
  • Boehringer Ingelheim$184
  • United Therapeutics Corporation$183
  • Sanofi$158
  • plus $603 from 10 others

What the payments were for

  • Travel & lodging$1,47316%
  • Food & beverage$1,95822%
  • Education$5,50062%

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,931 in reported general payments places this provider in the 80th percentile of 133 pulmonary disease providers in Oklahoma.

See all pulmonary disease providers in Oklahoma

Medicare billing

Part B allowed, 2024
$16,422
Medicare patients
62
Services billed
210

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breztri AerosphereBudesonide/Glycopyr/Formoterol37$27,578
Stiolto RespimatTiotropium Br/Olodaterol Hcl33$15,030
Varenicline Tartrate11$1,353
Albuterol Sulfate HfaAlbuterol Sulfate44$1,269
Azelastine Hcl30$691
Prednisone18$34

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere$444$27,57837 claims
Boehringer IngelheimStiolto Respimat$184$15,03033 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 133 pulmonary disease providers in Oklahoma.

Other pulmonary disease in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →